Most pharma buyers treat Paragraph IV diligence like paperwork. That’s why they get burned.
Paragraph IV filings are supposed to be a warning system. A signal that a generic manufacturer may challenge a brand’s patent protections—and that the commercia…
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore Read Post »
Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline, underwriting a deal, or forecasting exclusivity value in Asia-Pacific, here’s the uncomfortable truth: “patent term” is n…
Drug patent expiry dates aren’t just legal milestones—they’re revenue calendars.
If you’re in pharma commercial, you already know the pain: a competitor’s “inevitable” launch date shows up on a slide deck, then suddenly it’s real—pricing pressure, form…
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign Read Post »
Sell the line before the patent breaks.
In pharma manufacturing, the most valuable time isn’t when the patent expires—it’s the months before the market opens and competitors flood in. Yet many equipment suppliers still operate like the race starts on…
The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/
DrugChatter: How does lyrica affect liver function? Read Post »
The “Smarter Monopoly” Debate Is Here—and It’s About to Get Louder
For years, the pharmaceutical industry has lived under a familiar tension: innovation needs protection, but patients need access. Standard drug patents are one way to balance that equat…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Most business development teams wait for the “cliff” to arrive—then scramble to win the scramble.
But in biologics, the cliff is predictab…
Generic competition isn’t just a legal event—it’s a business strategy.
For years, the industry narrative has been simple: once a patent expires, generics arrive, prices fall, and the market resets. But the real story—especially in branded pharmaceuti…
Patients aren’t asking “about patents.” They’re asking, “Will I be able to afford my medicine?”
If you’ve spent any time around drug pricing conversations lately, you’ve probably noticed a pattern: the most searched questions online rarely sound like l…
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Evergreen strategies aren’t new—but the playbook is getting faster, smarter, and harder to see.
For pharma teams, the real risk isn’t just that a brand files another patent. It’s that the brand files the right kind of patent—at the right time—using the…
Get new actionable insights and updates from BiotechBlog
